{"id":1419,"date":"2026-03-30T09:34:48","date_gmt":"2026-03-30T09:34:48","guid":{"rendered":"https:\/\/rovi.es\/proyecto-laisolid\/?p=1419"},"modified":"2026-03-30T09:34:56","modified_gmt":"2026-03-30T09:34:56","slug":"rovi-and-biotalentum-collaborate-to-boost-regenerative-medicine-within-the-ipcei-med4cure-framework","status":"publish","type":"post","link":"https:\/\/rovi.es\/proyecto-laisolid\/en\/rovi-and-biotalentum-collaborate-to-boost-regenerative-medicine-within-the-ipcei-med4cure-framework\/","title":{"rendered":"ROVI and BioTalentum collaborate to boost regenerative medicine within the IPCEI Med4Cure framework"},"content":{"rendered":"\n
Both companies will cooperate in developing customized three-dimensional polymeric scaffolds to encapsulate pancreatic-derived spheroids, and in conducting a feasibility study on the solid filling of bioink components.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

ROVI and BioTalentum have signed a collaboration agreement aimed at exploring developments in the field of regenerative medicine through the design of three-dimensional polymeric scaffolds that ensure cell viability and retention within target tissues.<\/p>\n\n\n\n

The initiative is part of the first Important Project of Common European Interest in the healthcare sector, IPCEI Med4Cure, designed to support and promote research, innovation, and the initial industrial deployment of medical products, as well as innovative processes for pharmaceutical manufacturing, where collaboration is a central pillar for strengthening biomedical innovation across Europe.<\/p>\n\n\n\n

The alliance encompasses projects presented by both companies. On one hand, ROVI\u2019s LAISOLID project, focused on developing technologies for aseptic filling of polymeric matrices, and methodologies to accelerate clinical drug development using predictive models. The LAISOLID project is funded by CDTI under the Recovery, Transformation, and Resilience Plan associated with IPCEI Med4Cure. On the other hand, BioTalentum\u2019s CARDIABETTER project, which aims to produce pancreatic islets from human pluripotent stem cells and develop xenotransplantation technologies for genetically \u201chumanized\u201d porcine hearts, thus contributing to two advanced therapeutic strategies based on GMP-quality stem cells, scaled and modernized.<\/p>\n\n\n\n

Through joint efforts, ROVI and BioTalentum aim to advance regenerative medicine by developing customized 3D polymeric scaffolds capable of encapsulating spheroids containing human pancreatic cells, with the ultimate goal of preserving their viability and biological function over extended periods.<\/p>\n\n\n\n

The design of the scaffolds included in the collaboration focuses on bioprinting polymeric matrices with mechanical properties and internal architectures optimized for the metabolic requirements of the spheroids. Once optimal parameters for 3D printing and cell culture are established, the goal is to create a 3D platform that enables long-term maintenance of these organoids.<\/p>\n\n\n\n

The agreement also includes a feasibility study to carry out the solid filling of the bioink components used in bioprinting by adapting ROVI\u2019s innovative solid-filling technology.<\/p>\n\n\n\n

Regenerative medicine represents an innovative approach to restoring or replacing damaged tissues and cellular functions through advanced technologies such as 3D bioprinting, biomaterials, and complex cell cultures. These strategies open new possibilities for disease modeling, advanced therapy development, and optimization of technological platforms that facilitate the translation of regenerative medicine research into clinical and industrial applications.<\/p>\n\n\n\n

Such initiatives constitute a significant scientific advance by integrating cell biology knowledge, materials science, and biomedical engineering into a single technological platform. The ability to design 3D scaffolds with tailored mechanical properties and internal architectures to the metabolic needs of specialized cells improves the stability, functionality, and long-term maintenance of complex cellular models, thereby consolidating new pathways for progress in regenerative medicine.<\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n

About IPCEI Med4Cure<\/strong><\/p>\n\n\n\n

IPCEI Med4Cure is the first European project in the healthcare sector aimed at promoting research, innovation, and the initial industrial deployment of medical products, as well as innovative manufacturing processes in the pharmaceutical industry. Its objectives include addressing diseases for which there are no satisfactory means of prevention or treatment and enabling the European Union to better prepare for emerging health threats. Furthermore, it contributes to the goals of the European Industrial Strategy, the Pharmaceutical Strategy for Europe, the Cancer Plan for Europe, the new European Research Area, and the Green Deal.<\/p>\n\n\n\n

About BioTalentum<\/strong><\/strong><\/p>\n\n\n\n

Founded in 2005 in Hungary, BioTalentum is a biotechnological company specializing in research and development with human stem cells. The company develops cellular models for disease research, in vitro<\/em> toxicology, and regenerative medicine, and offers advanced platforms for 3D microtissues and predictive cultures for preclinical testing. BioTalentum maintains an extensive collection of healthy and pathological iPSC lines for personalized studies, with expertise spanning neurobiology, cardiac tissue engineering, and beta-cell therapies. The company is a leading R&D player in Central Europe, actively participating in European programs such as FP6, FP7, Horizon 2020, and Horizon Europe. (https:\/\/biotalentum.eu\/<\/a>)<\/p>\n\n\n\n

About ROVI<\/strong><\/strong><\/p>\n\n\n\n

ROVI is a pan-European pharmaceutical company engaged in the research, development, licensed manufacturing, and commercialization of small molecules and biological specialties. The company, which is undergoing continuous international expansion, operates subsidiaries in Portugal, Germany, the United Kingdom, Italy, France, and Poland, maintains a diversified portfolio of more than 40 marketed products. Among these, its flagship product, bemiparin, is available in over 60 countries worldwide. In addition, ROVI markets its internally developed enoxaparin biosimilar across Europe, with a presence in approximately 60 countries.<\/p>\n\n\n\n

The company continues to advance its proprietary ISM\u00ae<\/sup> platform technology, a leading research initiative in the field of extended-release drug delivery. For more information, visit www.ROVI.es<\/a>.<\/p>\n\n\n\n